Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification

Significant advances have been made in the understanding, diagnosis, and treatment of MN. These advances have been aided substantially by the discovery of novel antigens in MN, and their importance will increase further as the proposed new classification based on target antigens in MN is implemented. Once this routine is established more widely, the role of new antigens in MN disease pathogenesis and their associated clinical determinants will rapidly expand and will eventually allow more precision medicine to be used in MN disease management. With these new advances, classification of MN as primary versus secondary is no longer sufficient; instead, identification and classification of each form of MN, based on the target antigen, are critical. This consensus report sets forth a proposal on classification that is based on target-antigen identification, along with relevant disease and medication associations, when present.